T. Rowe Price Investment Management
VERV

T. Rowe Price Investment Management’s Verve Therapeutics VERV Stock Holding History

T. Rowe Price Investment Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,491,949
Closed -$11.4M – 739
2025
Q1 		$11.4M Buy
2,491,949
+139,350
+6% +$933K 0.01% 556
2024
Q4 		$13.3M Sell
2,352,599
-72,474
-3% -$409K 0.01% 542
2024
Q3 		$11.7M Sell
2,425,073
-2,103,639
-46% -$12.2M 0.01% 545
2024
Q2 		$22.1M Sell
4,528,712
-47,712
-1% -$300K 0.01% 494
2024
Q1 		$60.8M Buy
4,576,424
+1,402,072
+44% +$18.6M 0.04% 361
2023
Q4 		$44.3M Buy
3,174,352
+1,069,054
+51% +$13.3M 0.03% 400
2023
Q3 		$27.9M Buy
2,105,298
+3,937
+0.2% +$63.4K 0.02% 445
2023
Q2 		$39.4M Buy
2,101,361
+95,234
+5% +$1.59M 0.03% 404
2023
Q1 		$28.9M Buy
2,006,127
+206,477
+11% +$4.04M 0.02% 432
2022
Q4 		$34.8M Buy
1,799,650
+544,834
+43% +$14.4M 0.03% 400
2022
Q3 		$43.1M Buy
+1,254,816
New +$40M 0.03% 365

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Investment Management's VERV Position: Q2 2025 in Review

T. Rowe Price Investment Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 2,491,949 shares — an estimated $11.4M sold.

T. Rowe Price Investment Management first reported a position in VERV in Q3 2022 and held it in 11 quarters. The position peaked at $60.8M in Q1 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • T. Rowe Price Investment Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 2,491,949 Verve Therapeutics shares in Q2 2025, an estimated $11.4M.
  • T. Rowe Price Investment Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 11 quarters.
  • T. Rowe Price Investment Management's Verve Therapeutics position peaked at $60.8M in Q1 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.